Osborn Williams & Donohoe’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Osborn Williams & Donohoe’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$8.18M	Sell	56,698 -26,075	-32%	-$5.03M	1.07%	28
2019 Q4	$16.9M	Buy	82,773 +1,865	+2%	+$340K	1.69%	8
2019 Q3	$6.5M	Buy	80,908 +2,450	+3%	+$208K	0.65%	45
2019 Q2	$7.4M	Buy	78,458 +880	+1%	+$76K	0.76%	42
2019 Q1	$6.76M	Buy	77,578 +4,610	+6%	+$383K	0.7%	42
2018 Q4	$4.09M	Buy	72,968 +2,580	+4%	+$158K	0.72%	45
2018 Q3	$5.75M	Buy	70,388 +600	+0.9%	+$42.3K	0.9%	35
2018 Q2	$2.44M	Hold	69,788	–	–	0.41%	69
2018 Q1	$1.43M	Hold	69,788	–	–	0.25%	92
2017 Q4	$1.98M	Hold	69,788	–	–	0.34%	80
2017 Q3	$2.17M	Hold	69,788	–	–	0.39%	72
2017 Q2	$2.21M	Hold	69,788	–	–	0.4%	71
2017 Q1	$1.58M	Buy	69,788 +22,788	+48%	+$563K	0.29%	89
2016 Q4	$1.03M	Hold	47,000	–	–	0.19%	103
2016 Q3	$1.24M	Buy	+47,000	New	+$933K	0.24%	97

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Osborn Williams & Donohoe's RETA Position: Q1 2020 in Review

Osborn Williams & Donohoe reduced its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 32% in Q1 2020, selling an estimated $5.03M and leaving 56,698 shares worth $8.18M. The position accounts for 1.07% of the portfolio, ranked #28.

Osborn Williams & Donohoe first reported a position in RETA in Q3 2016 and has held it in 15 quarters since. The position peaked at $16.9M in Q4 2019. 214 funds tracked by Wall St. Rank hold RETA as of Q1 2020.

Osborn Williams & Donohoe held 56,698 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $8.18M as of Q1 2020.
Osborn Williams & Donohoe sold 26,075 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2020, an estimated $5.03M.
Reata Pharmaceuticals, Inc. Class A Common Stock made up 1.07% of Osborn Williams & Donohoe's portfolio in Q1 2020, its #28 holding.
Osborn Williams & Donohoe first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2016 and has held it in 15 quarters since.
Osborn Williams & Donohoe's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $16.9M in Q4 2019.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2020.

Based on Osborn Williams & Donohoe's 13F filing for Q1 2020, filed 4 May 2020.